Our Clients Are Using Psychedelics. Now What? (1 of 5)
Updated: 1 day ago
The conversation you’re already having, whether or not you know it
You did not need to say yes to this work. It found you anyway.
A client sits across from you and mentions, almost in passing, that they went to a ceremony last month. Or that they’ve been microdosing before their morning runs. Or that a friend gave them a baggie of mushrooms and they took it alone on a Tuesday night because things had gotten unbearable and they didn’t know what else to do.
You did not bring this into the room. They did. And now you have a choice, made in real time, with no supervision, no protocol, and about four seconds to decide: what do you say next?
This is not a hypothetical. This is Tuesday.
Across every specialty, every modality, every corner of the field, clients are using psychedelics and earth medicines — psilocybin, ayahuasca, bufo, ketamine, MDMA, San Pedro, ibogaine — and they are doing it whether or not their clinician has any training in it, any framework for it, or any comfort with it at all. Decriminalization has moved faster than curricula. Psychedelic use and access have moved faster than clinical training and the translation of emerging research into everyday practice. Culture has moved faster than clinical consensus. And somewhere in that gap stands you, the person your client actually trusts enough to tell.
Here is what almost twenty years of holding space for transformation has taught me: the gap doesn’t close itself. And the two most common ways clinicians try to close it both fail the client.
The Gatekeeper
The first failure looks responsible. It sounds like caution. It says: I can’t condone illegal substance use, or let’s focus on what we know works, or simply changes the subject before the client finishes their sentence.
This clinician isn’t wrong to be careful — they’re wrong to be closed.
Because what the client hears, underneath the clinical language, is: don’t bring this here. And clients are extremely good at hearing that message. They stop bringing it there. They don’t stop using the medicine. They just stop telling you about it, which means you’ve lost the one thing therapy actually requires — the truth of what’s happening in their life.
Gatekeeping doesn’t prevent the use. It only guarantees you won’t be in the room for it.
The Cheerleader
The second failure looks like the opposite of the first, and it is just as dangerous. This clinician has their own relationship to these medicines — maybe a profound one — and when the client brings it up, something in the clinician lights up too. Curiosity turns into encouragement. Encouragement turns into subtle direction. Before long the clinician is recommending dosages they have no training or scope to recommend, validating a ceremony they know nothing about, or quietly living out their own unprocessed material through their client’s experience.
This clinician isn’t malicious. They’re unsupervised.
And an unsupervised clinician projecting their own psychedelic enthusiasm onto a client’s care is not a minor ethical footnote — it is one of the more serious risks in this entire emerging field, precisely because it doesn’t look like harm. It looks like support.
The Third Posture
There is a stance between these two, and it is not a compromise or a middle ground. It is a distinct clinical competency, and it can be learned.
Neither gatekeeper nor cheerleader. The psychedelic clinician occupies a third posture.
It starts with a simple reorientation: your job is not to approve of the medicine or to endorse the medicine. Your job is to stay clinically present to what is actually happening in your client’s inner world, before and after their experience — and to have enough real knowledge of these substances, their risk profiles, their contraindications, and their integration demands that your presence is useful rather than performative.
That requires actual competencies most graduate programs never taught you: how to recognize medical and psychiatric contraindications and engage in responsible harm-reduction conversations when a client tells you they intend to have an experience you cannot attend or facilitate. How to assess experiences that may involve spiritual emergence, psychiatric destabilization, or some complicated intersection of the two — experiences that can look remarkably similar while calling for very different forms of assessment and response. How to hold a harm-reduction conversation without it collapsing into either endorsement or refusal. How to do integration work that actually integrates something, instead of just admiring it in session for fifty minutes.
None of this requires you to have sat in ceremony yourself. It requires training, a framework for discernment, and — critically — a community of practice you can turn to when a case exceeds what you know, because it will.
You don’t have to become a psychedelic therapist.
But you can no longer afford to be a therapist who knows nothing about psychedelics.
What This Series Is
Over the next several essays, I want to build that framework with you, piece by piece: how to inhabit this third posture without collapsing into either gatekeeping or cheerleading; what this work asks you to confront in yourself before you can competently hold it for someone else; what responsible harm reduction and clinical discernment actually require; what real integration practice looks like beyond the buzzword; and why doing this work without a peer field is its own clinical risk.
I’ve spent almost two decades in the room with people at the edges of transformation, and the last several years specifically at the intersection of clinical practice and psychedelic and earth medicine work. Some of what I’ve learned is going into a book, The Psychedelic Clinician — but a book is not where this work gets built.
It gets built in training, in supervision, in consultation with other clinicians who are in the same room you are, on the same Tuesday, with the same four seconds to decide what to say next.
That’s what I’m building here.
Trainings. Group and private consultation. A place for clinicians who are done pretending this isn’t already happening in their caseload.
If that’s you, I’d like you to stay for the rest of this series — and when you’re ready, there’s a seat for you in the room.
Comments